This article first appeared on GuruFocus.
-
Revenue: INR10,263 crores, up 24% YoY highest ever quarterly revenue.
-
Operating EBITDA: INR2,156 crores, up 28% YoY; margin at 21%.
-
Formulations Revenue: INR9,102 crores, up 24% YoY; ~89% of consolidated revenue.
-
API Revenue: INR1,162 crores, up 21% YoY; ~11% of overall revenue.
-
U.S. Revenue: INR4,555 crores (USD477 million), up 25% YoY; 10 products launched, 7 ANDAs filed, 12 final approvals.
-
Europe Revenue: EUR288 million, constant currency growth of 18%.
-
Growth Markets Revenue: INR1,026 crores (USD107 million), up 16% YoY.
-
ARV Formulation Revenue: USD38 million, supported by stable volumes.
-
Gross Margin: 61.2% vs. 59.7% in the prior-year period; contribution of INR6,280 crores.
-
R&D Expenditure: INR376 crores vs. INR344 crores in the previous quarter.
-
Capital Expenditure: USD89 million total USD47 million towards development capabilities, USD42 million towards strategic priorities.
-
Cash Flow: USD146 million generated during the quarter after funding strategic investments.
-
Net Cash Position: USD189 million at quarter end.
-
Finance Cost: Average of 4.9%.
-
Profit After Tax: INR1,124 crores.
-
FY27 Guidance: Double...